AOD9604

Περιγραφή

AOD9604 (Anti-Obesity Drug 9604) is a synthetic peptide consisting of the C-terminal fragment (amino acids 177-191) of human growth hormone (hGH), modified with an additional tyrosine residue for stability. Originally developed in the 1990s as a potential anti-obesity treatment, AOD9604 is studied for its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) in adipose tissue, particularly in stubborn areas like the abdomen, without the anabolic, hyperglycemic, or insulin-desensitizing effects associated with full-length hGH. Preclinical animal studies and early-phase human trials (including a 2000s Australian study) demonstrated that AOD9604 could promote significant fat loss, improve lipid profiles, and enhance body composition when administered subcutaneously, with effects potentially independent of IGF-1 elevation or growth hormone axis stimulation. In research and anecdotal wellness contexts, AOD9604 is often used at doses of 300-500 mcg per day (typically injected once daily in the morning or before bed) for cycles of 4-12 weeks, with users reporting gradual reductions in body fat percentage, preserved muscle mass, and improved energy during calorie-restricted periods. It is frequently discussed as a “hGH fragment” for non-hormonal fat-burning support, appealing to those seeking targeted weight management without the risks of full hGH therapy. However, AOD9604 is not FDA-approved for any therapeutic, weight loss, or medical use as of 2026—it remains an investigational research peptide, with no large-scale, definitive clinical trials confirming long-term efficacy or safety in humans. The FDA has flagged it in certain contexts as a bulk substance presenting potential safety risks for compounding or human use. Reported side effects from user experiences are generally mild (injection-site irritation, headaches, fatigue, or mild nausea), but unknowns remain regarding immunogenicity, long-term metabolic effects, or potential interactions. It is prohibited by WADA for athletes and should never be used without supervision from a qualified healthcare provider experienced in peptides, as self-administration carries risks of contamination from unregulated sources, improper dosing, adverse reactions, or legal issues. Prioritize evidence-based weight management strategies—consult a professional to assess suitability, source from reputable compounding pharmacies if considered under guidance (where permitted), and stay informed on regulatory or emerging research developments. AOD9604 is not a substitute for proven diet, exercise, or approved medical therapies.